All Industries

Top Therapeutics Companies

765 Therapeutics companies, sorted by total funding raised.

Satellite Bio

Develops off-the-shelf liver cell therapies that deliver functional hepatocytes to restore liver ...

Cambridge, United States11–50Biotech, Life Sciences
Series BTotal funding$215.5MJan 2024
Connect BiopharmaIPO

Clinical-stage biopharmaceutical company developing therapies for inflammatory diseases including...

San Diego, United States51–200Biotech, Healthcare
Corporate RoundTotal funding$215.2MMar 2026
Adicet Bio

Menlo Park, CA & Boston, MA

Redwood City, United States51–200Biotech, Healthcare
Venture RoundTotal funding$211.0MOct 2025
Affinia Therapeutics

An innovative gene therapy company with a proprietary platform for rationally designed adeno-asso...

Waltham, United States51–200Biotech, Therapeutics
Series CTotal funding$210.0MOct 2025
Aera Therapeutics

Biotechnology company developing next-generation genetic medicines using a proprietary protein na...

Boston, United States51–200Biotech, Drug Discovery
Series ATotal funding$193.0MFeb 2023
Centrexion Therapeutics

Centrexion Therapeutics Corp. is focused on advancing the treatment of chronic moderate to severe...

Boston, United States11–50Biotech, Drug Discovery
Venture RoundTotal funding$192.4MJun 2023
TScan TherapeuticsIPO

Clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies...

Waltham, United States51–200Biotech, Healthcare
Corporate RoundTotal funding$190.0MDec 2024
Callio Therapeutics

Callio Therapeutics is a clinical-stage biotech developing dual-payload antibody-drug conjugates,...

Seattle, United States1–10Biotech, Oncology
Series ATotal funding$187.0MMar 2025
TmunityClosed

Develops next-generation engineered T-cell therapies (CAR-T and TCR) for oncology, partnering wit...

Philadelphia, United States1–10Biotech, Therapeutics
Venture RoundTotal funding$185.0MDec 2022
Caribou BiosciencesIPO

Clinical-stage biopharmaceutical company developing genome-edited allogeneic CAR-T cell therapies...

Berkeley, United States51–200Biotech, Healthcare
Corporate RoundTotal funding$181.0MJul 2023
Jasper TherapeuticsIPO

Clinical-stage biotechnology company developing briquilimab, a monoclonal antibody targeting c-Ki...

Redwood City, United StatesBiotech, Drug Discovery
Private EquityTotal funding$181.0MAug 2026
Turnstone BiologicsClosed

Clinical-stage biotech developing Selected TIL (tumor-infiltrating lymphocyte) cell therapies for...

Ottawa, Canada51–200Biotech, Therapeutics
Series DTotal funding$174.9MJul 2021
Attralus

Public company, acquired by Bayer

Biotech, Healthcare
Venture RoundTotal funding$172.0MFeb 2024
AviadoBio

AviadoBio is a biotechnology company developing transformative gene therapies for neurodegenerati...

London, United Kingdom51–200Biotech, Genomics
Series BTotal funding$168.5MApr 2025
AB
ARMO BioSciencesAcquired

Late-stage immuno-oncology company developing pegilodecakin (AM0010) and immune-modulating biolog...

Redwood City, United States11–50Biotech, Therapeutics
Series CTotal funding$167.0MAug 2017
Numab

Numab designs and develops a new class of powerful therapeutics for the treatment of severe disea...

Biotech, Drug Discovery
Extension RoundTotal funding$165.0MJan 2025
Editas MedicineIPO

Editas Medicine is building a leading gene editing company that uses CRISPR genome editing to dev...

Cambridge, United States201–500Biotech, Genomics
Series BTotal funding$163.0MAug 2015
AkouosAcquired

Akouos advances precision genetic therapies with the potential to restore, improve, and preserve ...

Boston, United States51–200Biotech, Therapeutics
Series BTotal funding$162.5MMar 2020
Addex TherapeuticsIPO

Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally ava...

Plan-les-Ouates, Switzerland11–50Biotech, Drug Discovery
Extension RoundTotal funding$155.9MAug 2022
Moonwalk Biosciences

Develops precision epigenetic medicines targeting adipose biology and cardiometabolic disease usi...

South San Francisco, United States11–50Biotech, Drug Discovery
Series BTotal funding$155.5MSep 2026
EpizymeIPO

Biopharmaceutical company that is creating innovative drugs for major diseases based on important...

Cambridge, United States201–500Biotech, Drug Discovery
Growth EquityTotal funding$154.0MNov 2019
Sagimet BiosciencesIPO

A clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat impo...

San Mateo, United States11–50Biotech, Drug Discovery
Growth EquityTotal funding$153.5MFeb 2021
Avencell

AvenCell is a clinical-stage cell therapy company developing controllable, allogeneic CAR-T thera...

Watertown, United States51–200Biotech, Genomics
GrantTotal funding$152.0MJun 2025
Magenta TherapeuticsAcquired

Clinical-stage biotechnology company developing novel medicines to harness the curative power of ...

Cambridge, United States51–200Biotech, Therapeutics
Series CTotal funding$150.5MApr 2018
Cullinan Oncology

Cullinan Therapeutics develops clinical-stage therapies that modulate the immune system to treat ...

Cambridge, United States51–200Biotech, Healthcare
Series ATotal funding$150.0MOct 2017